Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 15/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294489 | 0.85 | LRRK2 (0.41) | LNPEP | |
| SCHEMBL19463811 | 0.81 | GRM5 (0.36) | LNPEPROCK1 | |
| Hydrochloric Acid SCHEMBL31044701 | 0.79 | SLC6A4 (0.47) | ROCK1ROCK2KCNH2 | |
| SCHEMBL3301120 | 0.79 | LRRK2 (0.43) | — | |
| SCHEMBL12247661 | 0.79 | GRM5 (0.45) | LNPEPLOXLOXL2FDPS | |
| SCHEMBL17396913 | 0.78 | LNPEP (0.35) | LNPEPROCK1 | |
| SCHEMBL13791566 | 0.78 | LOX (0.50) | LNPEPLOXLOXL2ABL1 | |
| SCHEMBL13791457 | 0.77 | GRM5 (0.46) | LNPEPLOXLOXL2ABL1 | |
| SCHEMBL190777 | 0.77 | LOX (0.45) | LNPEPLOXLOXL2FDPSABL1 | |
| SCHEMBL13802796 | 0.77 | LNPEP (0.52) | LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| CN-102803265-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2012-11-28 | — | — | CN | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | LNPEP 2818/4885LOX 1136/4885LOXL2 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.